These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15912577)

  • 1. In vitro characterization of an Fe(8) cluster as potential MRI contrast agent.
    Rodríguez E; Roig A; Molins E; Arús C; Quintero MR; Cabañas ME; Cerdán S; Lopez-Larrubia P; Sanfeliu C
    NMR Biomed; 2005 Aug; 18(5):300-7. PubMed ID: 15912577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging.
    Langereis S; de Lussanet QG; van Genderen MH; Meijer EW; Beets-Tan RG; Griffioen AW; van Engelshoven JM; Backes WH
    NMR Biomed; 2006 Feb; 19(1):133-41. PubMed ID: 16450331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Gd-DTPA-induced signal enhancements in rat brain C6 glioma among different pulse sequences in 3-Tesla magnetic resonance imaging.
    Sato H; Enmi J; Teramoto N; Hayashi T; Yamamoto A; Tsuji T; Naito H; Iida H
    Acta Radiol; 2008 Mar; 49(2):172-9. PubMed ID: 18300142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equilibrium signal intensity mapping, an MRI method for fast mapping of longitudinal relaxation rates and for image enhancement.
    Surányi P; Kiss P; Ruzsics B; Brott BC; Simor T; Elgavish GA
    Magn Reson Imaging; 2007 Jun; 25(5):641-51. PubMed ID: 17540275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CH3-DTPA-Gd (NMS60) as a new MR contrast agent: early phase II study in brain tumors and dual dynamic contrast-enhanced imaging.
    Ito M; Ogino H; Oshima H; Shiraki N; Shibamoto Y; Kasai H; Mase M; Kawamura Y; Miyati T
    Magn Reson Imaging; 2006 Jun; 24(5):625-30. PubMed ID: 16735185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography.
    Kiessling F; Heilmann M; Lammers T; Ulbrich K; Subr V; Peschke P; Waengler B; Mier W; Schrenk HH; Bock M; Schad L; Semmler W
    Bioconjug Chem; 2006; 17(1):42-51. PubMed ID: 16417250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilage.
    Welsch GH; Mamisch TC; Hughes T; Zilkens C; Quirbach S; Scheffler K; Kraff O; Schweitzer ME; Szomolanyi P; Trattnig S
    Invest Radiol; 2008 Sep; 43(9):619-26. PubMed ID: 18708855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular imaging by a polyarginine derived cell penetrating peptide labeled magnetic resonance contrast agent, diethylenetriamine pentaacetic acid gadolinium.
    Guo YM; Liu M; Yang JL; Guo XJ; Wang SC; Duan XY; Wang P
    Chin Med J (Engl); 2007 Jan; 120(1):50-5. PubMed ID: 17254488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gadolinium complexes with polyoxometalates as potential MRI contrast agents.
    Li Z; Li W; Li X; Pei F; Li Y; Lei H
    Magn Reson Imaging; 2007 Apr; 25(3):412-7. PubMed ID: 17371733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
    Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
    J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths.
    Yrjänä SK; Vaara T; Karttunen A; Koivukangas J
    Invest Radiol; 2008 Apr; 43(4):267-75. PubMed ID: 18340251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field.
    Livramento JB; Helm L; Sour A; O'Neil C; Merbach AE; Tóth E
    Dalton Trans; 2008 Mar; (9):1195-202. PubMed ID: 18283380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model.
    Runge VM; Biswas J; Wintersperger BJ; Baumann SS; Jackson CB; Herborn CU; Patel T
    Invest Radiol; 2006 Mar; 41(3):244-8. PubMed ID: 16481906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
    Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
    Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging of mesenchymal stem cells labeled with dual (MR and fluorescence) agents in rat spinal cord injury.
    Shen J; Zhong XM; Duan XH; Cheng LN; Hong GB; Bi XB; Liu Y
    Acad Radiol; 2009 Sep; 16(9):1142-54. PubMed ID: 19660710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a conjugated gadolinium and cisplatin-gelatin possessing properties as an intravascular contrast agent for MR imaging.
    Sonoda A; Nitta N; Ohta S; Seko A; Jo J; Morikawa S; Tabata Y; Takahashi M; Murata K
    Eur J Radiol; 2009 Sep; 71(3):570-5. PubMed ID: 18502598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved T(1)-weighted dynamic contrast-enhanced MRI to probe microvascularity and heterogeneity of human glioma.
    Pauliah M; Saxena V; Haris M; Husain N; Rathore RK; Gupta RK
    Magn Reson Imaging; 2007 Nov; 25(9):1292-9. PubMed ID: 17490844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced susceptibility-weighted perfusion MRI (DSC-MRI) in a glioma model of the rat brain using a conventional receive-only surface coil with a inner diameter of 47 mm at a clinical 1.5 T scanner.
    Ulmer S; Reeh M; Krause J; Herdegen T; Heldt-Feindt J; Jansen O; Rohr A
    J Neurosci Methods; 2008 Jul; 172(2):168-72. PubMed ID: 18538856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.